# Lengthening Adalimumab Dosing Interval in Quiescent Crohn's Disease Patients

> **NCT03172377** · PHASE4 · UNKNOWN · sponsor: **Radboud University Medical Center** · enrollment: 174 (estimated)

## Conditions studied

- Crohn Disease in Remission
- Crohn Disease

## Interventions

- **OTHER:** Lengthening adalimumab dosing interval

## Key facts

- **NCT ID:** NCT03172377
- **Lead sponsor:** Radboud University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-05-03
- **Primary completion:** 2022-10
- **Final completion:** 2022-10
- **Target enrollment:** 174 (ESTIMATED)
- **Last updated:** 2022-10-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03172377

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03172377, "Lengthening Adalimumab Dosing Interval in Quiescent Crohn's Disease Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03172377. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*